PONATINIB
Manner of administration:Oral
Restriction
Indication: Acute lymphoblastic leukaemia
Treatment phase: Initial treatment
Restriction
Indication: Acute lymphoblastic leukaemia
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 2 | DPMQ: $5,874.00 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Iclusig | |||||
Manner of administration:Oral
Restriction
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Initial treatment
Restriction
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Initial treatment
Restriction
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: First continuing treatment
Restriction
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Subsequent continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 5 | DPMQ: $5,874.00 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Iclusig | |||||
Manner of administration:Oral
Restriction
Indication: Acute lymphoblastic leukaemia
Treatment phase: Initial treatment
Restriction
Indication: Acute lymphoblastic leukaemia
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 2 | DPMQ: $5,874.00 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Iclusig | |||||